These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 22763244)

  • 1. Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei.
    Sørensen O; Flatmark K; Reed W; Wiig JN; Dueland S; Giercksky KE; Larsen SG
    Eur J Surg Oncol; 2012 Oct; 38(10):969-76. PubMed ID: 22763244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei.
    Andréasson H; Graf W; Nygren P; Glimelius B; Mahteme H
    Eur J Surg Oncol; 2012 Oct; 38(10):962-8. PubMed ID: 22809859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
    Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
    Elias D; Gilly F; Quenet F; Bereder JM; Sidéris L; Mansvelt B; Lorimier G; Glehen O;
    Eur J Surg Oncol; 2010 May; 36(5):456-62. PubMed ID: 20227231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
    Yan TD; Links M; Xu ZY; Kam PC; Glenn D; Morris DL
    Br J Surg; 2006 Oct; 93(10):1270-6. PubMed ID: 16838392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
    Chua TC; Yan TD; Smigielski ME; Zhu KJ; Ng KM; Zhao J; Morris DL
    Ann Surg Oncol; 2009 Jul; 16(7):1903-11. PubMed ID: 19387742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate.
    Chua TC; Liauw W; Zhao J; Morris DL
    Ann Surg; 2011 Apr; 253(4):769-73. PubMed ID: 21475018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
    Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
    World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
    Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
    J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.
    Cashin PH; Graf W; Nygren P; Mahteme H
    Eur J Surg Oncol; 2012 Jun; 38(6):509-15. PubMed ID: 22475555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
    Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
    Saxena A; Yan TD; Chua TC; Morris DL
    Ann Surg Oncol; 2010 May; 17(5):1291-301. PubMed ID: 20039212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
    Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.